Deyuan Zhong
Overview
Explore the profile of Deyuan Zhong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang Y, Zhong D, Shang J, Yan H, Su Y, Chen Y, et al.
BMC Cancer
. 2025 Mar;
25(1):418.
PMID: 40055613
Purpose: To evaluate the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (PA-HAIC) plus programmed death-1 (PD-1) inhibitors versus PA-HAIC alone for hepatocellular carcinoma (HCC) patients with microvascular...
2.
Liu C, Yang Q, Zhong D, Yan H, Gu H, Yang X, et al.
J Cardiothorac Surg
. 2024 Nov;
19(1):639.
PMID: 39614304
Background: Chondrosarcoma primarily occurs in the pelvis and femur, with occasional cases in the ribs. Surgical resection remains the main treatment method for costal chondrosarcoma. However, complete resection often leads...
3.
4.
Single-cell profiling reveals the metastasis-associated immune signature of hepatocellular carcinoma
Zhong D, Shi Y, Ma W, Liang Y, Liu H, Qin Y, et al.
Immun Inflamm Dis
. 2024 May;
12(5):e1264.
PMID: 38780041
Aim: Metastasis is the leading cause of mortality in hepatocellular carcinoma (HCC). The metastasis-associated immune signature in HCC is worth exploring. Methods: Bioinformatic analysis was conducted based on the single-cell...
5.
Liang Y, Zhong D, Zhang Z, Su Y, Yan S, Lai C, et al.
BMC Cancer
. 2024 Mar;
24(1):343.
PMID: 38491347
No abstract available.
6.
Liang Y, Zhong D, Zhang Z, Su Y, Yan S, Lai C, et al.
BMC Cancer
. 2024 Mar;
24(1):291.
PMID: 38438842
Background: For chronic hepatitis B virus (HBV) infection patients, increasing evidence has demonstrated the effectiveness of expanding the indications and applicable population for antiviral therapy. However, the expanded indication of...
7.
Liang Y, Zhong D, Yang Q, Tang Y, Qin Y, Su Y, et al.
J Hepatocell Carcinoma
. 2024 Feb;
11:373-383.
PMID: 38410699
Background: Tumor metastasis is the leading cause of high mortality in hepatocellular carcinoma (HCC). The metastasis-related HCC microenvironment is characterized by high heterogeneity. Single-cell RNA sequencing (scRNA-seq) may aid in...
8.
Liang Y, Yang R, Shang J, Zhong D, Yang Q, Su Y, et al.
J Cancer Res Clin Oncol
. 2023 Sep;
149(18):16461-16471.
PMID: 37707573
Background: Transarterial chemoembolization (TACE), one of the most commonly used postoperative adjuvant therapy for HCC, has achieved satisfactory outcomes. This study aimed to explore the prognostic value of lung immune...
9.
Shang J, Li L, Lai C, Feng T, Yao Y, Zhong D, et al.
Int Immunopharmacol
. 2023 Sep;
124(Pt A):110743.
PMID: 37657247
Background: The efficacy of immune checkpoint inhibitors remains limited in non-small cell lung cancer (NSCLC). Natural killer (NK) cells serve as the key element of innate immunity and play an...
10.
Feng T, Lai C, Yuan Q, Yang W, Yao Y, Du M, et al.
iScience
. 2023 Aug;
26(9):107538.
PMID: 37636059
Liver fibrosis, a rising cause of chronic liver diseases, could eventually develop into cirrhosis and liver failure. Current diagnosis of liver fibrosis relies on pathological examination of hepatic tissues acquired...